CR20120301A - Procedimiento de identificación de animales vacunados frente a brucella - Google Patents

Procedimiento de identificación de animales vacunados frente a brucella

Info

Publication number
CR20120301A
CR20120301A CR20120301A CR20120301A CR20120301A CR 20120301 A CR20120301 A CR 20120301A CR 20120301 A CR20120301 A CR 20120301A CR 20120301 A CR20120301 A CR 20120301A CR 20120301 A CR20120301 A CR 20120301A
Authority
CR
Costa Rica
Prior art keywords
vaccinated animals
identification procedure
animals against
against brucella
mammals
Prior art date
Application number
CR20120301A
Other languages
English (en)
Inventor
Dolset Maria Grillo
Zabalza Beatriz Amorena
Andres Cara Damian De
Robles Edgardo Moreno
Olarte Esteban Chaves
Verri Caterina Guzman
Diaz Carlos Chacon
Original Assignee
Consejo Superior Investigacion
Univ Navarra Publica
Univ Nac De Costa Rica Una
Univ De Costa Rica Ucr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion, Univ Navarra Publica, Univ Nac De Costa Rica Una, Univ De Costa Rica Ucr filed Critical Consejo Superior Investigacion
Publication of CR20120301A publication Critical patent/CR20120301A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/098—Brucella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/23—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Brucella (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43595—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from coelenteratae, e.g. medusae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere al uso de una cepa de Brucella spp. que expresa la proteína Green Flourescent Protein (GFP) en la elaboración de medicamentos para la prevención de la brucelosis en mamíferos, a las vacunas frente a la brucelosis, y al método para la identificación de los mamíferos a los que se les ha administrado dichas vacunas. Preferiblemente, el método de la invención es un inmunoensayo, y aún más preferiblemente es un ensayo inmunoabsorbente ligado a enzimas (ELISA).
CR20120301A 2009-12-03 2012-06-01 Procedimiento de identificación de animales vacunados frente a brucella CR20120301A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200931101A ES2372187B8 (es) 2009-12-03 2009-12-03 Procedimiento de identificación de animales vacunados frente a brucella.

Publications (1)

Publication Number Publication Date
CR20120301A true CR20120301A (es) 2013-02-27

Family

ID=44114638

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120301A CR20120301A (es) 2009-12-03 2012-06-01 Procedimiento de identificación de animales vacunados frente a brucella

Country Status (7)

Country Link
EP (1) EP2508201A4 (es)
CN (1) CN102781468A (es)
CR (1) CR20120301A (es)
ES (1) ES2372187B8 (es)
MX (1) MX2012006303A (es)
PE (1) PE20121648A1 (es)
WO (1) WO2011067446A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019101993A1 (en) 2017-11-24 2019-05-31 Consejo Superior De Investigaciones Científicas (Csic) A modified brucella vaccine strain for the treatment of brucellosis
CN110863031A (zh) * 2019-09-29 2020-03-06 安徽医科大学第一附属医院 一种检测布鲁菌病治疗效果的标志物及其应用
CN111796091B (zh) * 2020-07-20 2023-09-08 天康生物制药有限公司 用于区分动物感染布氏杆菌或布氏杆菌菌影疫苗的试剂盒
WO2022271201A2 (en) * 2021-01-07 2022-12-29 International Advantage, Inc. Ace2 and tmprss2 gene expression as predictive markers of covid-19 severity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7416878B2 (en) * 2002-12-12 2008-08-26 The United States Of America As Represented By The Secretary Of The Army Immunogenic compositions including rough phenotype Brucella host strains and complementation DNA fragments
CN101240290B (zh) * 2008-02-29 2011-06-15 杭州师范大学 一种含绿色荧光蛋白基因的植物转基因表达载体及其构建方法和应用
US20100226942A1 (en) * 2008-10-30 2010-09-09 Schurig Gerhardt G Producing an immune response for reducing the risk of developing brucellosis
CN101586120B (zh) * 2009-07-15 2011-06-15 中国农业科学院哈尔滨兽医研究所 狂犬病病毒Flury-LEP疫苗株反向遗传操作系统及LEP绿色荧光蛋白重组病毒载体

Also Published As

Publication number Publication date
EP2508201A4 (en) 2013-08-07
ES2372187A1 (es) 2012-01-17
MX2012006303A (es) 2012-09-07
ES2372187B1 (es) 2012-11-26
ES2372187B8 (es) 2013-04-29
PE20121648A1 (es) 2012-12-24
CN102781468A (zh) 2012-11-14
EP2508201A1 (en) 2012-10-10
WO2011067446A1 (es) 2011-06-09

Similar Documents

Publication Publication Date Title
EA201291105A1 (ru) Пероральная вакцина, содержащая антиген и агонист toll-подобного рецептора
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
AR078423A1 (es) Vacunas dirigidas a las celulas de langerhans
CL2012001650A1 (es) Fragmento fab de anticuerpo que se une específicamente a la glicoproteína vi (gpvi) humana e induce un fenotipo de reducción de gpvi; composición farmacéutica que comprende dichos fragmentos fab de anticuerpo anti-gpvi; polinucleótido que los codifica; método para su preparación; su uso para evitar el reconocimiento de un fragmento fab de anticuerpo por anticuerpos preexistentes; y su uso para evitar la activación plaquetaria mediante el enmascaramiento del c-terminal de dicho fragmento fab.
PE20150646A1 (es) Metodos de tratamiento de una tauopatia
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
CR20120371A (es) Antagonistas de pcsk9
GT201400049A (es) "anticuerpos a pcsk9 y usos de los mismo"
CL2017001585A1 (es) Anticuerpos anti-c5 y métodos para su uso
CR20130621A (es) Anticuerpos anti-angptl3 y usos de los mismos
MX2017003268A (es) Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.
CR10298A (es) Metodos y composiciones para antagonismo de rage
CO6721041A2 (es) Anticuerpo anti-pcsk9 y métodos de uso
CR20130132A (es) Anticuerpos contra metalproteasa-9 de matriz
AR083747A1 (es) Anticuerpos anti-il-23
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
CO6362024A2 (es) Anticuerpos humanos de alta afinidad para el receptor il-4 humano
CR20110544A (es) Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7
MX2022002106A (es) Formulaciones de vacuna de vial unico.
CL2012003094A1 (es) Anticuerpo bivalente aislado o fragmento bivalente del mismo, que actua sobre lrp6 potenciando una señal wnt al agrupar uno o mas receptores lrp6 en presencia de una proteina de union de lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; y su uso para tratar cancer.
MX2019001767A (es) Anticuerpos monoclonales que se unen al dominio de union a lipidos de la proteina de la capside del virus de la hepatitis c (vhc).
BR112013007514A2 (pt) anticorpo isolado, uso da composição e método
CR20120301A (es) Procedimiento de identificación de animales vacunados frente a brucella
BR112015008036A2 (pt) população de peptídeos isolados, método para detectar em uma amostra um anticorpo, método para diagnosticar erliquiose monocítica e/ou granulocítica e kit